IWC
MLTX icon

Integrated Wealth Concepts’s MoonLake Immunotherapeutics MLTX Stock Holding History

Integrated Wealth Concepts’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.9K Buy
+1,998
New +$36.2K ﹤0.01% 3562

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrated Wealth Concepts's MLTX Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 1,998 shares worth $38.9K. The stake represents ﹤0.01% of the portfolio and ranks #3562 among its holdings.

172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Integrated Wealth Concepts held 1,998 shares of MoonLake Immunotherapeutics worth $38.9K as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #3562 holding.
  • 172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.